求助6篇Springer数据库文献

w2503

1. Clinical Applications of Activated Immune Cells! n# E/ h' ~0 A& Q: b5 Q3 {+ N
http://www.springerlink.com/content/p77j27781g92vm53/$ W$ [8 a! d8 N6 G- h) v
6 k/ j( G. ~8 P: W& c/ H
2. Increased effector–target cell conjugate formation due to HLA restricted specific antigen recognition 5 S" K4 u* @1 ^, C
http://www.springerlink.com/content/l667677h47l82363/
; W0 D3 }! X0 q4 i. d( i$ R8 |3 O5 q1 F
3. Selective Immortalization of Tumor-Specific T Cells to Establish Long-Term T-Cell Lines Maintaining Primary Cell Characteristics . f4 s4 v2 [1 ]/ M' l: |
http://www.springerlink.com/content/lg3m7811288qg086/#section=54582&page=1
' r- W7 ?% n/ D8 E9 B4 u9 m
% U* a; X5 n+ S( }; T1 u/ E3 }4. Extending the Use of Adoptive T Cell Immunotherapy for Infections and Cancer
% o/ r: H: L' |http://www.springerlink.com/content/u67186375261m831/
6 b' O9 K) M( m- l" {
( ]9 Q+ {% i7 B5. Gene Immunotherapy for Non-Small Cell Lung Cancer
/ [% q' ~- J! W$ [$ vhttp://www.springerlink.com/content/w2j70l9rx1857154/#section=671351&page=14 m# `0 X+ A5 s( c- k1 d
; a# |# {; W! q  M  d; l. y2 e
6. Designing TCR for Cancer Immunotherapy
% W! ^" I' v- {- Yhttp://www.springerlink.com/content/v7607l2v0243k7m7/#section=83660&page=1" R+ F# l& a2 G9 D7 e
$ G5 A+ j7 G$ s# v  f* p
谢谢7 ]8 a' R& I+ @0 ]! ?* G+ R" i

2 Z# b! X/ E! w1 l- z6 P, v
* a/ w0 w$ b+ j6 N
5 Z, [8 z  F6 y3 G0 }5 X8 k, p 4 F1 \9 j2 c. A$ @- u, G

sunlu36

1 ok

sunlu36

3 ok4 y- P( P- U5 k) Q% s/ l/ C' Z

sunlu36

4   

sunlu36

5     

sunlu36

6     

w2503

回复 sunlu36 的帖子; g- u  [4 _$ a" ]7 F  O# w8 e

9 \/ {' D. Z; u) w谢谢

w2503

) Z2 ?4 H* `6 h+ b

' O- \! t& \) R+ k( ]8 o4 p6 P还差第2篇
+ D2 o6 u: S7 H7 k2 g9 K+ T8 c0 B. R2. Increased effector–target cell conjugate formation due to HLA restricted specific antigen recognition
4 E7 j2 b3 ^0 I/ ^! d4 dhttp://www.springerlink.com/content/l667677h47l82363/

ceming

2 check the attached file

w2503

回复 ceming 的帖子
4 J" `8 o/ x% {8 q, g9 }; t. d5 x- H. w, _
谢谢